Oncology Peer Review On-The-Go: Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Podcast

CancerNetwork’s latest podcast episode dissects and article from the journal ONCOLOGY® focusing on 4 PARP inhibitors investigated for the treatment of advanced prostate cancer.

This episode features an article published in the Journal ONCOLOGY titled “Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.”

CancerNetwork® spoke with the corresponding author, Jun Gong, MD, a medical oncologist at Cedars-Sinai Medical Center, to discuss the 4 PARP inhibitors that have undergone significant investigation for the treatment of patients with metastatic castrate-resistant prostate cancer. While elaborating on the use of PARP inhibitors, Gong also discussed the importance and potential value of successfully integrating these agents into prostate cancer practice.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content